M. Lapresa

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Nicoletta Colombo, Michele Peiretti, Gabriella Parma et al. · Annals of Oncology · 2010 · 180 citations · Full text

Gynecological Surgery, Medicine, Cancer Management +6

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Domenica Lorusso, Gabriella Ferrandina, Nicoletta Colombo et al. · Gynecologic Oncology · 2019 · 94 citations

Medicine, Mito End-2, Gynecology +6

Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study

Angiolo Gadducci, Enrico Sartori, Fabio Landoni et al. · Journal of Clinical Oncology · 2004 · 61 citations · Full text

Gynecological Malignancies in Elderly Patients: Is Age 70 a Limit to Standard-Dose Chemotherapy? An Italian Retrospective Toxicity Multicentric Study

Marcello Ceccaroni, Giuseppe Roberto D’Agostino, Gabriella Ferrandina et al. · Gynecologic Oncology · 2002 · 46 citations

Geriatric Oncology, Oncology, Elderly Patients +12

Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.

Domenica Lorusso, Gabriella Ferrandina, Nicoletta Colombo et al. · Journal of Clinical Oncology · 2015 · 44 citations

Phase Ii Trial, Medicine, Mito End-2 Trial +14